Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality

被引:35
作者
Larranaga, N. [1 ]
Galceran, J. [2 ]
Ardanaz, E. [3 ]
Franch, P. [4 ]
Navarro, C. [5 ]
Sanchez, M. J. [6 ]
Pastor-Barriuso, R. [7 ]
机构
[1] Basque Country Reg Author, Publ Hlth Dept Gipuzkoa, Basque Country Canc Registry, San Sebastian, Spain
[2] Pere Virgili Hlth Res Inst, Fdn Soc Canc Res & Prevent, Tarragona Canc Registry, Reus, Spain
[3] Navarre Publ Hlth Inst, Navarre Canc Registry, Pamplona, Spain
[4] Directorate Gen Publ Hlth & Participat, Dept Epidemiol, Mallorca Canc Registry, Palma De Mallorca, Spain
[5] Hlth Author, Dept Epidemiol, Murcia Canc Registry, Murcia, Spain
[6] Andalusian Sch Publ Hlth, Granada Canc Registry, Granada, Spain
[7] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain
关键词
incidence; mortality; prostate neoplasms; Spain; PSA; trends; INTERPRETING TRENDS; SURVEILLANCE SERIES; RISING INCIDENCE; RISK; OVERDIAGNOSIS; SURVIVAL; DECREASE; EPIDEMIOLOGY; DIAGNOSIS; AUSTRIA;
D O I
10.1093/annonc/mdq087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Materials and methods: The time trend in invasive prostate cancer incidence from 1975 to 2004 was studied by combining data from 13 Spanish population-based cancer registries. Change-point Poisson regression models were fitted for all men and for two age groups (45-64 and 65+ years). Age-period-cohort models were used to study cohort and period effects. In addition, we studied the time trend in prostate cancer mortality in Spain for the period 1980-2007. Results: Incidence increased annually by 1.3% from 1975 to 1990 and by 7.3% thereafter. Until 1990, the percentage increase was low and indeed similar for both age groups. While the subsequent increase in the two age groups was greater, this was particularly marked among the youngest men, with a decrease being observed in age groups > 85 years in the last quinquennium. Mortality increased by an annual figure of 0.7% until 1998, after which it decreased by 3.6% per annum until 2007. Conclusions: Despite the dramatic rise in incidence from 1990 onwards, mainly due to opportunistic screening, prostate cancer mortality was only observed to decline slowly from 1998. If prostate-specific antigen screening remains at a similar level in Spain, overdiagnosis may well become an important chronic side-effect and health problem.
引用
收藏
页码:iii83 / iii89
页数:7
相关论文
共 50 条
  • [31] Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence
    Wilt, Timothy J.
    Scardino, Peter T.
    Carlsson, Sigrid V.
    Basch, Ethan
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03):
  • [32] Prostate-specific antigen kinetics in localized and advanced prostate cancer
    Fitzpatrick, John M.
    Banu, Eugeniu
    Oudard, Stephane
    [J]. BJU INTERNATIONAL, 2009, 103 (05) : 578 - 587
  • [33] Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
    Rove, Kyle O.
    Crawford, E. David
    [J]. WORLD JOURNAL OF UROLOGY, 2012, 30 (02) : 137 - 142
  • [34] Recommendations on screening for prostate cancer with the prostate-specific antigen test
    Bell, Neil
    Gorber, Sarah Connor
    Shane, Amanda
    Joffres, Michel
    Singh, Harminder
    Dickinson, James
    Shaw, Elizabeth
    Dunfield, Lesley
    Tonelli, Marcello
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2014, 186 (16) : 1225 - 1234
  • [35] The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era
    Jahn, Jaquelyn L.
    Giovannucci, Edward L.
    Stampfer, Meir J.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (12) : 2795 - 2802
  • [36] Screening for Prostate Cancer With the Prostate-Specific Antigen Test A Review of Current Evidence
    Hayes, Julia H.
    Barry, Michael J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (11): : 1143 - 1149
  • [37] Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer
    Preston, Mark A.
    Batista, Julie L.
    Wilson, Kathryn M.
    Carlsson, Sigrid V.
    Gerke, Travis
    Sjoberg, Daniel D.
    Dahl, Douglas M.
    Sesso, Howard D.
    Feldman, Adam S.
    Gann, Peter H.
    Kibel, Adam S.
    Vickers, Andrew J.
    Mucci, Lorelei A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) : 2705 - +
  • [38] Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values
    Catalona, William J.
    Loeb, Stacy
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (02): : 265 - 270
  • [39] Impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy
    Kim, Jae Heon
    Doo, Seung Whan
    Yang, Won Jae
    Lee, Kwang Woo
    Lee, Chang Ho
    Song, Yun Seob
    Jeon, Yoon Su
    Kim, Min Eui
    Kwon, Soon-Sun
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (10) : 987 - 990
  • [40] Prostate-specific antigen screening, why have the guidelines changed?
    Sountoulides, Petros
    Moutzouris, Georgios
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1277 - 1281